Defbrotide
Mechanism :
Defibrotide augments plasmin enzymatic activity to hydrolyse fibrin clots. t reduces endothelial cell (EC) activation and increases EC-mediated fibrinolysis by increasing tissue plasminogen activator and thrombomodulin expression, as well as by decreasing von Willebrand factor and plasminogen activator inhibitor-1 expression.
Indication :
- Hepatic sinusoidal obstruction syndrome
Contraindications :
Known hypersensitivity to defibrotide or any component of the formulation; concomitant administration with systemic anticoagulant or fibrinolytic therapy.
Dosing :
>1 month:
IV:
6.25 mg/kg every 6 hours for at least 21 days and up to a maximum of 60 days.
Adverse Effect :
Hypotension, diarrhea, vomiting, nausea, haemorrhage, epistaxis, hyperuricemia, hypersensitivity reactions, graft versus host disease, sepsis.
Interaction :
Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant and anti-platelet effect of Thrombolytic Agents.
Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.
Hepatic Dose :
No dosage adjustments are recommended.